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Background: Many patients with type 2 diabetes
mellitus (T2DM) also have hypertension, which is com-
monly treated with thiazide diuretics, including hydro-
chlorothiazide (HCTZ). Canagliﬂozin, a sodium glucose
cotransporter 2 inhibitor developed for the treatment of
T2DM, lowers plasma glucose by inhibiting renal glucose
reabsorption, thereby increasing urinary glucose excretion
and mild osmotic diuresis. Because patients with T2DM
are likely to receive concurrent canagliﬂozin and HCTZ,
potential interactions were evaluated.
Objective: This study evaluated the effects of HCTZ
on the pharmacokinetic and pharmacodynamic pro-
perties and tolerability of canagliﬂozin in healthy
participants.
Methods: This Phase I, single-center, open-label,
ﬁxed-sequence, 2-period study was conducted in healthy
participants. During period 1, participants received
canagliﬂozin 300 mg once daily for 7 days, followed
by a 14-day washout period. During period 2, partic-
ipants received HCTZ 25 mg once daily for 28 days,
followed by canagliﬂozin 300 mg þ HCTZ 25 mg once
daily for 7 days. Blood samples were taken before and
several times after administration on day 7 of period 1
and on days 28 and 35 of period 2 for canagliﬂozin and
HCTZ pharmacokinetic analyses using LC-MS/MS.
Blood and urine samples were collected for up to
24 hours after canagliﬂozin administration on day 1 of
period 1 and day 35 of period 2 for pharmacodynamic
glucose assessment. Tolerability was also evaluated.
Results: Thirty participants were enrolled (16 men,
14 women; all white; mean age, 43.7 years). Canagli-
ﬂozin AUC during a dosing interval (T) at steady state
(AUCτ,ss) and Cmax at steady state (Cmax,ss) were
increased when canagliﬂozin was coadministered with698HCTZ, with geometric mean ratios (90% CI) of 1.12
(1.08–1.17) and 1.15 (1.06–1.25), respectively. AUCτ,ss
and Cmax,ss for HCTZ were similar with and without
canagliﬂozin coadministration. The 24-hour mean re-
nal threshold for glucose and mean plasma glucose
were comparable for canagliﬂozin alone and coadmi-
nistered with HCTZ. The change in 24-hour urine
volume from baseline was 0.1 L with canagliﬂozin
alone and 0.4 L with HCTZ alone and with canagli-
ﬂozin þ HCTZ. The overall incidence of adverse events
(AEs) was higher with canagliﬂozin þ HCTZ (69%)
than with canagliﬂozin (47%) or HCTZ (50%) alone;
most AEs were of mild severity. Overall, minimal
changes in serum electrolytes (eg, sodium, potassium)
were observed after coadministration of canagliﬂozin þ
HCTZ compared with individual treatments.
Conclusions: Adding canagliﬂozin treatment to
healthy participants on HCTZ treatment had no nota-
ble pharmacokinetic or pharmacodynamic effects; can-
agliﬂozin coadministered with HCTZ was generally
well tolerated, with no unexpected tolerability concerns.
ClinicalTrials.gov identiﬁer: NCT01294631. (Clin
Ther. 2014;36:698–710) & 2014 The Authors. Pub-
lished by Elsevier HS Journals, Inc. All rights reserved.
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Inhibiting renal glucose reabsorption by sodium glu-
cose co-transporter (SGLT2) is a novel therapeutic
approach to treating patients with type 2 diabetes
mellitus (T2DM).1,2 Canagliﬂozin is an SGLT2 inhib-
itor developed for the treatment of adults with
T2DM3–10; canagliﬂozin doses of 100 and 300 mg
have been approved in the United States.11 Canagli-
ﬂozin reduces plasma glucose by lowering the renal
threshold for glucose excretion (RTG) and increasing
urinary glucose excretion (UGE).12 The increase in
UGE results in a mild osmotic diuresis and a loss of
calories1,2,4,6,7; the osmotic diuretic effect of canagli-
ﬂozin is also associated with a reduction in intra-
vascular volume, which attenuates over time.11,13 In
clinical studies in patients with T2DM, canagliﬂozin
treatment improved glycemic control and reduced
body weight and systolic/diastolic blood pressure
(BP).4–10,14
Hypertension is a common comorbidity in patients
with T2DM.15,16 Hydrochlorothiazide (HCTZ) is a
thiazide diuretic indicated for the treatment of mild to
moderate hypertension. Thiazides work, at least in
part, by inhibiting sodium reabsorption in the distal
convoluted tubule (DCT).17,18 Oral administration of
HCTZ results in diuresis within 2 hours,19 indirectly
leading to an initial reduction in plasma volume that
attenuates with long-term treatment.20 The SGLT2
transporters targeted by canagliﬂozin, in contrast, are
located in the proximal convoluted tubule (PCT).1,2
Inhibition of SGLT2 by canagliﬂozin is predicted to
reduce both glucose and sodium resorption in the PCT,
leading to increased sodium delivery to the DCT.
Because both canagliﬂozin and HCTZ may contribute
to decreased sodium reabsorption via 2 different mech-
anisms targeting the PCT and the DCT, the effects of
the combined administration of canagliﬂozin þ HCTZ
on sodium concentration in the blood and on frac-
tional excretion (FE) of sodium in the urine are of
interest. Moreover, it is of interest whether these effects
of the 2 drugs on sodium excretion lead to greater
reductions in systolic and diastolic BP when the agents
are administered together relative to when each agent
is administered alone.
These questions are clinically relevant, given the
high prevalence of hypertension in patients with
T2DM and the common use of thiazide therapy in
this population, because it is likely that patients with
T2DM receive concurrent treatment with canagliﬂozin þMay 2014HCTZ. Thus, it is important to evaluate whether a
pharmacodynamic interaction could occur between
these 2 agents. In addition, because canagliﬂozin and
HCTZ are each associated with plasma volume reduc-
tions, it is also important to evaluate the tolerability of
canagliﬂozin þ HCTZ coadministration. The primary
objective of this Phase I study was to examine the
effects of HCTZ on the pharmacodynamic properties
of canagliﬂozin; secondary objectives were: (1) to
examine the effects of HCTZ on the pharmacokinetic
properties of canagliﬂozin; (2) to evaluate the effects of
canagliﬂozin on the pharmacokinetic properties of
HCTZ; and 3) to assess the tolerability of canagliﬂozin
coadministered with HCTZ in healthy participants.
PARTICIPANTS AND METHODS
Participants
Eligible participants were healthy men and women
aged 18 to 55 years. Participants were required to
have a body mass index of 18 to 30 kg/m2, body
weight Z50 kg, and a creatinine clearance (estimated
using the Cockcroft-Gault formula21) Z80 mL/min.
Exclusion criteria included, but were not limited to,
a history of or current clinically signiﬁcant medical
illness (including cardiac disease, hematologic disease,
lipid abnormalities, and/or diabetes mellitus); clini-
cally signiﬁcant abnormal values on hematology, clini-
cal chemistry, urinalysis, physical examination, vital
sign measurement, or 12-lead ECG as assessed by the
investigator at screening or on day 3 of the ﬁrst
treatment period; and current history of overactive
bladder with excessive urination frequency.
Study Design
This Phase I, single-center, open-label, ﬁxed-sequence,
2-period study was conducted in accordance with the
ethical principles that have their origin in the Declara-
tion of Helsinki and that are consistent with Good
Clinical Practice and other applicable regulatory require-
ments. Participants provided their written consent to
participate in the study before the performance of any
study-related activity. The consent form was approved
by both the sponsor and the reviewing independent
ethics committee.
The study consisted of 3 phases: (1) a screening
phase of up to 19 days; (2) two open-label treatment
periods, period 1 and period 2, with a 14-day washout
period between the 2 periods; and (3) a post-treatment
phase of up to 6 days (Figure 1). During period 1,699
Open-Label: Period 1
Baseline
Day −4
Day −3 Day −1 Day 1 Day 28 Day 29 Day 35 Day 36 Day 41 Day 46
Day −22
Baseline
Open-Label: Period 2
HCTZ 25 mg
HCTZ 25 mg +
CANA 300 mg
Tolerability
Assessment
Post-treatment
End-of-study
Follow-up
Day −3 Day −1 Day 1 Day 7 Day 8
Washout
Day 21
CANA 300 mgScreening
Figure 1. Study design. CANA ¼ canagliflozin; HCTZ ¼ hydrochlorothiazide.
Clinical Therapeuticsparticipants received canagliﬂozin 300 mg once daily
on days 1 to 7; during period 2, participants received
HCTZ 25 mg once daily for 28 days (days 1–28),
followed by the combination of canagliﬂozin 300 mg
þ HCTZ 25 mg once daily for 7 days (days 29–35).
Participants were domiciled at the study center during
days 3 to 8 of period 1, and days 3 to 1 and days
26 to 36 of period 2. Participants received standard-
ized meals while at the study center; the meals
contained sodium not exceeding 2.5 g/d and calcium
content 1 g/d.
Pharmacokinetic Evaluations
The pharmacokinetic proﬁles of canagliﬂozin and
HCTZ were obtained using blood samples (4 mL for
canagliﬂozin and 2 mL for HCTZ) taken before and at
0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours
after the administration of study drug. These proﬁles
were obtained for canagliﬂozin on day 7 of period 1, for
HCTZ on day 28 of period 2, and for both canagli-
ﬂozin and HCTZ on day 35 of period 2. In addition,
predose blood samples were obtained on days 5 and 6
of period 1 and on days 7, 14, and 21 of period 2.
EDTA plasma samples were analyzed to determine the
concentrations of canagliﬂozin with a validated LC-MS/
MS method (Frontage Company Ltd, Shanghai, People’s
Republic of China).22,23 A 13C6 analogue of canagliﬂozin
was used as the internal standard (IS). Brieﬂy, the sample
was processed using a liquid-liquid extraction with tert-
butyl methyl ether. The LC phase used a 5 cm  4.6 mm
column packed with XBridge C18 (Waters Corporation,
Milford, Massachusetts) with a mobile phase of ammo-
nium acetate 0.01 M (30%) and methanol (70%) and a
ﬂow rate of 1.2 mL/min. Quantiﬁcation was achieved by700MS/MS detection with an API 4000, equipped with
TurboIonSpray (TIS) interface (AB Sciex, Framingham,
Massachusetts) in the positive ion multiple reaction
monitoring mode. Canagliﬂozin and IS were monitored
at mass transitionsm/z 462.1- 267.0 andm/z 468.1-
273.0, respectively. The quantitation range was 5.00 to
10,000 ng/mL. The in-study performance of the quality-
control samples ranged from 94.5% to 114.8% intrarun
accuracy, with an inter-run %CV ranging from 3.9% to
9.9%. HCTZ samples were assayed with a validated
assay using Isolute SLEþ 96-well plates (Biotage LLC,
Charlotte, North Carolina) with tert-butyl methyl
ether.22,23 As the IS, a 15N2
13CD2 analogue of HCTZ
was used. Quantitation was done using a LC-MS/MS
method on the AB Sciex 5000, in negative TIS mode at
Pharmaceutical Product Development, LLC, Richmond,
Virginia. A Synergi Polar-RP column (80 Å, 2.0 75 mm,
4 μm) (Phenomenex, Inc, Torrance, California) was used.
Mobile phase consisted of an ammonium formate/
acetonitrile gradient from 74/26 to 26/74 (vol/vol) over
3 minutes with a ﬂow rate of 0.25 mL/min. HCTZ and
IS were monitored at mass transitions m/z 296.0 -
269.1 and m/z 301.0 - 271.3, respectively. The
quantitation range was 2.00 to 200 ng/mL. The in-
study performance of the quality-control samples ranged
from 95.7% to 115.0% intrarun accuracy, with an inter-
run %CV ranging from 4.0% to 5.4%.
The following pharmacokinetic parameters were
evaluated based on the individual plasma concentra-
tion–time data, using actual sampling times via non-
compartmental analysis with validated WinNonlin®
version 5.2.1 (Pharsight Corporation, Mountain View,
California): Cmax during a dosing interval at steady
state (Cmax,ss); trough plasma concentration beforeVolume 36 Number 5
D. Devineni et al.dosing or at the end of the dosing interval, except ﬁrst
dose (Ctrough); time to Cmax,ss (tmax,ss); and area under
the plasma concentration versus time curve during a
dosing interval (τ) at steady state (AUCτ,ss).
Pharmacodynamic Evaluations
Plasma glucose was assessed using blood samples
(2 mL each) obtained before and at 0.5, 1, 1.5, 2, 3, 4.5,
5, 6, 7, 8, 9.5, 10.5, 11, 12, 12.5, 14, 16, and 24 hours
after administration of canagliﬂozin on day 7 of period 1
and on day 35 of period 2. Urinary glucose was
evaluated using urine samples collected over 4 separate
intervals (0–4, 4–8, 8–12, and 12–24 hours) after
administration of canagliﬂozin on day 7 of period 1
and day 35 of period 2. Plasma samples and 1-mL
aliquots collected from each urine collection interval
were analyzed to determine glucose concentrations based
on spectrophotometry using the Roche hexokinase
method (Paciﬁc Biomarkers Inc, Seattle, Washington).
The following pharmacodynamic parameters were
evaluated: RTG, calculated for each scheduled urine
collection interval and for each 24-hour urine collec-
tion period; UGE, calculated for each scheduled urine
collection interval and cumulatively for each 24-hour
urine collection period (UGE0–24 h); and mean plasma
glucose concentration during 24 hours postdose
(MPG0–24 h) in periods 1 and 2. RTG during each
collection interval was calculated using the measured
plasma glucose proﬁles, UGE, and estimated glomer-
ular ﬁltration rate (obtained from the Modiﬁcation of
Diet in Renal Disease formula24) as previously
described,12,25 and the 24-hour mean RTG was
calculated as the weighted mean of the values ob-
tained over the different collection intervals. Values of
RTG were calculated only during canagliﬂozin or
canagliﬂozin þ HCTZ treatment because participants
treated with HCTZ alone had virtually no UGE.
MPG0–24 h was determined from the measured plasma
glucose proﬁles by calculating the AUC and dividing
by 24 hours (calculations performed using WinNonlin
version 5.2.1 [Pharsight Corporation]); all samples
collected within the 24-hour postdose time period
were included in the calculation.
Tolerability Assessment
Tolerability evaluations included reports of adverse
events (AEs), physical examination ﬁndings, vital sign
measurements, 12-lead ECG, hematology, clinical
chemistry, urinalysis, and speciﬁc renal function tests,May 2014as described later. Vital signs included triplicate supine
and 1-time standing systolic/diastolic BP and pulse rate
assessments, which were measured at several time
points on day 1 of both study periods (baseline) as
well as on day 7 in period 1 and on days 28 and 35 in
period 2. Orthostatic hypotension was deﬁned as a de-
crease in standing versus supine systolic BP420 mmHg
or a decrease in standing versus supine diastolic BP
410 mm Hg combined with an increase in standing
versus supine pulse rate 40 beats/min (bpm). Clinical
chemistry parameters were assessed in period 1 on day
1 predose (baseline) and day 8, and in period 2 on day
1 predose (baseline), day 29, and day 36, as well as at
the ﬁnal follow-up visit; the following serum chemistry
parameters were included: sodium, potassium, chlor-
ide, bicarbonate, creatinine, blood urea nitrogen
(BUN), urate, calcium, phosphate, and magnesium.
Measures of renal tubular function were also
evaluated; for each urine collection interval, parame-
ters included: total urine volume; urine pH; measured
creatinine clearance; and 24-hour excretion and FE of
urinary analytes, including sodium, potassium, cal-
cium, chloride, inorganic phosphate, and magnesium.
Measured creatine clearance was calculated from
measured serum and urine creatinine concentrations
as follows:
CrCl mL=min
 ¼ 10
6  UCr mmolð Þ
SCr  1440 min
where UCr is the measured 24-h cumulative excretion
of creatinine and SCr is the serum creatinine concen-
tration. Measured creatinine clearance was then ad-
justed for body surface area (BSA) to obtain CrCl in
units of mL/min/1.73m2 by multiplying the CrCl value
in mL/min by (1.73m2/BSA), where BSA is calculated
using Mosteller formula:
BSA m2
  ¼ weight kg½   height cm½ =3600 1=2
The evaluation of FE for the different analytes was
performed using the following equation:
FEanalyte ¼ 100 Analyteurine  Creatinineserum
 
=
Analyteserum  Creatinineurine
 
Statistical Analyses
The study was primarily designed as an estimation
study to evaluate the effects of HCTZ on the RTG
with canagliﬂozin. Thus, sample size was based on the
precision of the estimate of RTG. Based on data from a701
Clinical Therapeuticsprevious study of canagliﬂozin in healthy participants,
the intersubject %CV for 24-hour mean RTG was
estimated to be 21% after multiple doses of canagli-
ﬂozin 300 mg. Assuming an estimated intrasubject
%CV of 20% for 24-hour mean RTG, 24 participants
were considered sufﬁcient for the point estimate of the
ratio of 24-hour mean RTG for canagliﬂozin þ HCTZ
and canagliﬂozin alone to fall between 91% and 110%
of the true value, with 90% conﬁdence. Therefore, the
current study planned to enroll 30 participants to
ensure that 24 participants completed the study.
Pharmacokinetic parameters were determined from
individual plasma concentration–time data for canagli-
ﬂozin and HCTZ, and were summarized using de-
scriptive statistics. The effects of HCTZ at steady state
on the pharmacokinetic properties of canagliﬂozin
were evaluated using data from days 7 to 8 (canagli-
ﬂozin) of period 1 and days 35 to 36 (canagliﬂozin þ
HCTZ) of period 2; the effects of canagliﬂozin on the
steady-state pharmacokinetic properties of HCTZ
were evaluated using data from days 28 to 29 (HCTZ)
and days 35 to 36 (canagliﬂozin þ HCTZ) of period 2.
Linear mixed-effects models were ﬁt to the log-
transformed pharmacokinetic parameters (AUCτ,ss
and Cmax,ss) using SAS
® version 9.2 (SAS Institute
Inc, Cary, North Carolina), with treatment as a ﬁxed
effect and participant as a random effect. Least squares
(LS) means and intraparticipant variance were esti-
mated from the mixed-effects models and used to
determine the geometric mean ratio (GMR) of AUCτ,ss
and Cmax,ss of canagliﬂozin at steady state with or
without HCTZ, and the GMR of AUCτ,ss and Cmax,ss
of HCTZ with and without canagliﬂozin, as well as
the associated 90% CIs.
All pharmacodynamic parameters were summar-
ized using only descriptive statistics for each day of
measurement. To evaluate the effects of HCTZ on the
pharmacodynamic properties of canagliﬂozin, the
primary end point, 24-hour mean RTG, was analyzed
on a log scale, and UGE0–24 h was analyzed untrans-
formed, using original units (g), because UGE is often
close to zero in patients not treated with canagliﬂozin.
A mixed-effects model was ﬁt to the 24-hour mean
RTG (on a log scale) and UGE0–24 h data from periods
1 and 2, with treatment as a ﬁxed effect and parti-
cipant as a random effect. LS means were estimated
based on the mixed-effects model and used to calcu-
late the difference in 24-hour mean RTG (on a log
scale) and UGE0–24 h between coadministration of702canagliﬂozin þ HCTZ and administration of canagli-
ﬂozin alone, as well as the associated 90% CIs.
Estimated LS mean differences (on a log scale) and
associated 90% CIs for 24-hour mean RTG were
back-transformed to estimate the ratio of means
and associated 90% CIs for canagliﬂozin þ HCTZ
and canagliﬂozin alone, along with the difference in
24-hour mean RTG. The analysis of MPG0–24h was
similar to that of 24-hour mean RTG.
RESULTS
Participants
A total of 30 healthy participants (16 men
and 14 women; all white) were enrolled and received
Z1 dose of study drug; 28 participants (93%)
completed the study, and 2 participants were with-
drawn due to AEs. Mean (SD) age of the participants
was 43.7 (8.4) years, mean weight was 75.6 (9.4) kg,
and mean body mass index was 25.7 (2.2) kg/m2.
Pharmacokinetic Results
After repeated once-daily dosing alone, plasma
canagliﬂozin concentrations achieved steady state by
day 7. After administration of canagliﬂozin alone and
after coadministration with HCTZ, plasma canagliﬂo-
zin concentrations increased rapidly (median tmax,
1.0 hour with both treatments) (Figure 2). Plasma
HCTZ concentrations increased rapidly when HCTZ
was dosed alone and in combination with canagliﬂozin
(median tmax, 1.5 hours with both treatments)
(Figure 3). Coadministration of canagliﬂozin þ
HCTZ was associated with increases versus cana-
gliﬂozin alone of 12% in geometric LS mean
canagliﬂozin AUCτ,ss (27,942 and 24,896 ng  h/mL,
respectively; GMR [90% CI], 1.12 [1.08–1.17]) and
15% in geometric LS mean canagliﬂozin Cmax,ss (4350
and 3787 ng/mL; GMR [90%CI], 1.15 [1.06–1.25])
(Table I). Similar geometric LS mean HCTZ AUCτ,ss
(1049 and 1055 ng  h/mL; GMR [90% CI], 0.99
[0.95; 1.04]) and Cmax,ss (141 and 151 ng/mL; GMR
[90% CI], 0.94 [0.87; 1.01]) were observed when
HCTZ was administered with canagliﬂozin or alone.
Pharmacodynamic Results
The geometric LS mean RTG was 3.48 mmol/L
(62.6 mg/dL) with canagliﬂozin þ HCTZ and 3.22
mmol/L (58.0 mg/dL) with canagliﬂozin alone. With
canagliﬂozin þ HCTZ and canagliﬂozin alone, LS
mean UGE0–24h values were 41.34 and 42.34 g,Volume 36 Number 5
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Figure 2. Canagliflozin (CANA) plasma concentration–time profiles following the administration of CANA
with and without hydrochlorothiazide (HCTZ).
D. Devineni et al.respectively, and geometric LS mean MPG0–24h values
were 5.46 mmol/L (98.2 mg/dL) and 5.16 mmol/L
(93.0 mg/dL), respectively (Table II).
Tolerability
Adverse Events
Treatment-emergent AEs (TEAEs) were reported in
23 of 30 participants (77%); 14 participants (47%)
had TEAEs during treatment with canagliﬂozin alone
in period 1, 15 participants (50%) during treatment
with HCTZ alone in period 2, and 20 participants
(69%) during coadministration of canagliﬂozin and200 HCTZ
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Figure 3. Hydrochlorothiazide (HCTZ) plasma concentr
HCTZ with and without CANA.
May 2014HCTZ in period 2. Two serious AEs were reported
(lymphadenopathy [assessed by investigator as doubt-
fully related to study drugs] and tonsillitis [assessed by
investigator as not related to study drugs], in the same
participant during canagliﬂozin þ HCTZ treatment),
both of which resolved.
There were 2 discontinuations due to AEs (1 during
treatment with HCTZ alone [forearm fracture after a fall;
participant denied dizziness or lightheadedness at the
time of this event and it was considered by the inves-
tigator as unrelated to study drug], and the other during
canagliﬂozin þ HCTZ treatment [lymphadenopathy]).HCTZ + CANA
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ation–time profiles following the administration of
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Table I. Plasma pharmacokinetic properties of canagliflozin (CANA) and hydrochlorothiazide (HCTZ) alone
and in combination.
Geometric Least Squares Mean Arithmetic Mean (SD)
CANA 300 mg
(n ¼ 28)
CANA 300 mg þ
HCTZ 25 mg
(n ¼ 28) GMR (90% CI)*
CANA 300 mg
(n ¼ 30)
CANA 300 mg þ
HCTZ 25 mg
(n ¼ 28)
Canagliﬂozin
AUCτ,ss, ng  h/mL 24,896 27,942 1.12 (1.08–1.17) 25,112 (6071) 28,552 (6016)
Cmax,ss, ng/mL 3787 4350 1.15 (1.06–1.25) 3820 (767) 4490 (1143)
tmax,ss, h — — — 1.00 (1.00–1.50)
† 1.00 (0.62–2.00)†
HCTZ
AUCτ,ss, ng  h/mL 1055 1049 0.99 (0.95–1.04) 1056 (184) 1068 (208)
Cmax,ss, ng/mL 151 141 0.94 (0.87–1.01) 154 (33.6) 144 (32.1)
tmax,ss, h — — — 1.50 (0.50–3.00)
† 1.50 (0.62–5.00)†
GMR ¼ geometric mean ratio; AUCτ,ss ¼ AUC during a dosing interval (τ) at steady state; Cmax,ss ¼ Cmax during a dosing
interval during steady state; tmax,ss ¼ time to Cmax,ss.
*GMR and 90% CI for CANA + HCTZ relative to CANA alone or HCTZ alone.
†For tmax,ss, arithmetic mean (range) is provided.
Clinical TherapeuticsThere were no reports of hypoglycemia. Pollakiuria
was reported in 2 participants (both during treatment
with HCTZ alone); 1 participant had an AE related to
volume depletion (orthostatic hypotension, reported
during canagliﬂozin þ HCTZ treatment). FiveTable II. Pharmacodynamic properties of canagliflo
hydrochlorothiazide (HCTZ).
Geometric Least Squ
CANA 300 mg
(n ¼ 28)
C
HC
24-h mean RTG
mmol/L 3.22
mg/dL 58.0
UGE0–24 h, g
† 42.34
MPG0–24 h
mmol/L 5.16
mg/dL 93.0
GMR ¼ geometric mean ratio; MPG0–24 h ¼ mean plasma g
for glucose excretion; UGE0–24 h ¼ urinary glucose excretion du
*GMR and 90% CI for CANA + HCTZ relative to CANA alone.
†Values are least squares mean.
‡Difference in least squares means between CANA + HCTZ rela
704participants reported rash during treatment with
canagliﬂozin alone (all episodes were localized and
mild in severity). Three participants reported mild,
localized fungal infection of the skin during treatment
with canagliﬂozin alone. There were 2 reports ofzin (CANA) alone and in combination with
ares Mean
GMR (90% CI)*
ANA 300 mg þ
TZ 25 mg (n ¼ 28)
3.48 1.08 (1.05–1.11)
62.6
41.34 1.00 (3.09–1.09)‡
5.46 1.06 (1.04–1.07)
98.2
lucose during 24 hours postdose; RTG ¼ renal threshold
ring 24 hours postdose.
tive to CANA alone.
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D. Devineni et al.syncope that occurred during coadministration of
canagliﬂozin þ HCTZ, both mild in severity; 1 of
the events was considered by the investigator as
doubtfully related to study drugs, and the other event
was considered possibly related to study drugs. All
AEs resolved by the end-of-study visit or last follow-
up visit.
Laboratory Parameters
Mean serum sodium, potassium, and chloride con-
centrations were relatively unchanged during treatment
with canagliﬂozin alone and were slightly decreased
during administration of HCTZ alone and of canagli-
ﬂozin þ HCTZ (Table III). Mean serum urate and
bicarbonate concentrations were decreased with canagli-
ﬂozin alone and increased with HCTZ treatment. Other
serum chemistry parameters, including calcium, phos-
phate, and magnesium concentrations, changed mini-
mally during the study period.
Renal Function
Small increases in serum creatinine were seen with
canagliﬂozin alone and with canagliﬂozin coadministeredTable III. Summary of serum laboratory parameters.*
Parameter
CANA 300 mg (n ¼ 30) HCTZ 25 mg (
Baseline,
Mean
Δ,† Mean
(SE)
Baseline,
Mean
Δ,‡
(
Bicarbonate 28.0 1.3 (0.3) 27.8 þ1.
BUN 5.7 þ0.7 (0.1) 5.5 þ0.
Calcium 2.3 0.00 (0.01) 2.4 0.0
Chloride 101.8 0.03 (0.27) 101.8 4.
Creatinine║ 80.4 þ2.1 (0.9) 79.2 0.
Magnesium 0.8 þ0.03 (0.01) 0.8 þ0.0
Phosphate 1.2 þ0.01 (0.02) 1.2 þ0.0
Potassium 4.5 0.03 (0.06) 4.5 0.
Sodium 137.7 0.3 (0.3) 137.6 1.
Urate║ 294.4 76.1 (5.6) 283.7 þ57.
CANA ¼ canagliﬂozin; HCTZ ¼ hydrochlorothiazide; SE ¼ stan
*Values are mmol/L unless otherwise noted.
†Mean change from baseline at day 8 (period 1).
‡Mean change from baseline at day 29 (period 2).
§Mean change from baseline at day 36 (period 2).
║Values are μmol/L.
May 2014with HCTZ, and increases in BUN were observed
during each treatment period (Table III); serum
creatinine and BUN returned to baseline levels by
the end-of-study visit. No notable changes in meas-
ured creatinine clearance were observed after any
treatment (Table IV).
The change from baseline in mean 24-hour urine
volume was þ0.4 L with HCTZ alone and with
coadministration with canagliﬂozin, and was 0.1 L
with canagliﬂozin alone (Table IV). Changes from
baseline in urine pH during treatment with canagli-
ﬂozin alone, HCTZ alone, and coadministration of
canagliﬂozin þ HCTZ were þ0.5, þ1.7, and þ0.7,
respectively. During treatment with canagliﬂozin
alone, HCTZ alone, and canagliﬂozin þ HCTZ,
changes from baseline in the amount of urinary
sodium excretion were þ3.6, 8.9, and 24.8 mmol/
24 h, respectively; changes in FEsodium were þ0.02%,
0.04%, and 0.09%, respectively. Changes from
baseline in the 24-hour excretion of potassium were
þ2.4, þ17.5, and þ3.7 mmol/24 h during treatment
with canagliﬂozin alone, HCTZ alone, and canagli-
ﬂozin þ HCTZ, respectively, with changes inn ¼ 29) CANA 300 mg þ HCTZ 25 mg (n ¼ 28)
Mean
SE)
Baseline,
Mean
Δ,§ Mean
(SE)
9 (0.4) 27.7 þ4.1 (0.5)
7 (0.1) 5.5 þ1.7 (0.2)
2 (0.01) 2.4 0.01 (0.02)
4 (0.4) 101.9 7.1 (0.4)
5 (1.0) 79.1 þ5.9 (0.9)
2 (0.01) 0.8 þ0.09 (0.01)
1 (0.02) 1.2 0.03 (0.02)
5 (0.1) 4.5 0.9 (0.1)
7 (0.4) 137.5 2.1 (0.4)
2 (4.0) 282.7 þ2.3 (8.0)
dard error; BUN ¼ blood urea nitrogen.
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Table IV. Summary of renal function parameters.
Parameter
CANA 300 mg HCTZ 25 mg CANA 300 mg þ HCTZ 25 mg
No. of
Participants
Baseline,
Mean Δ, Mean (SE)
No. of
Participants
Baseline,
Mean Δ, Mean (SE)
No. of
Participants
Baseline,
Mean Δ, Mean (SE)
24-h urine volume, L* 30 3.0 0.1 (0.1) 29 2.5 þ0.4 (0.1) 28 2.5 þ0.4 (0.2)
Urine pH† 30 5.5 þ0.5 (0.2) 29 5.5 þ1.7 (0.1) 28 5.5 þ0.7 (0.2)
Measured CrCl,
mL/min/1.73 m2*,‡
29 108.8 þ1.5 (2.1) 29 108.0 þ4.7 (2.1) 28 107.6 3.8 (2.6)
Urinary analytes
Calcium, n 29 29 28
Amount, mmol/24 h 3.4 þ0.02 (0.15) 3.6 1.3 (0.2) 3.5 1.1 (0.3)
Fractional excretion, % 0.9 þ0.00 (0.03) 0.9 0.3 (0.05) 0.9 0.3 (0.07)
Chloride, n 29 28 20
Amount, mmol/24 h 42.9 þ2.2 (2.9) 66.4 þ3.2 (3.8) 67.1 12.0 (3.5)
Fractional excretion, % 0.3 þ0.02 (0.02) 0.4 þ0.03 (0.03) 0.4 0.01 (0.03)
Magnesium, n 29 29 28
Amount, mmol/24 h 4.2 0.2 (0.2) 4.2 þ1.0 (0.2) 4.2 þ0.1 (0.2)
Fractional excretion, % 3.0 0.2 (0.1) 3.0 þ0.6 (0.1) 3.0 0.1 (0.1)
Phosphate, n 29 29 28
Amount, mmol/24 h 30.1 þ0.9 (0.9) 29.9 þ3.3 (0.9) 29.6 þ2.9 (1.0)
Fractional excretion, % 15.4 þ0.4 (0.4) 15.4 þ1.3 (0.4) 15.4 þ3.2 (0.5)
Potassium, n 29 29 28
Amount, mmol/24 h 74.8 þ2.4 (3.0) 74.1 þ17.5 (2.3) 73.8 þ3.7 (2.7)
Fractional excretion, % 10.0 þ0.4 (0.3) 9.9 þ3.7 (0.5) 9.9 þ4.4 (0.5)
Sodium, n 29 29 28
Amount, mmol/24 h 45.2 þ3.6 (3.5) 77.0 8.9 (4.4) 77.2 24.8 (4.7)
Fractional excretion, % 0.2 þ0.02 (0.02) 0.3 0.04 (0.02) 0.3 0.09 (0.02)
CANA = canagliﬂozin; CrCl ¼ creatinine clearance; HCTZ = hydrochlorothiazide; SE = standard error.
*Baseline is day 1 for all treatment groups.
†Baseline is day 2 for all treatment groups.
‡Calculated based on 24-hour urine collection in period 1 and period 2.
Clinical TherapeuticsFEpotassium of þ0.4%, þ3.7%, and þ4.4%, respec-
tively. FEcalcium was decreased and FEmagnesium was
increased with HCTZ alone; these FE values did not
change with the addition of canagliﬂozin.
Vital Signs
Overall, small or no changes in systolic/diastolic BP
and pulse were observed, and none were considered
clinically adverse. In period 1, after canagliﬂozin treat-
ment alone (on day 7), slight decreases from baseline
were observed in mean supine (range, 1.0 to
5.4 mm Hg) and standing (range, 2.5 to
10.7 mm Hg) systolic BP values, and mean supine
(range, –0.3 to 4.5 mm Hg) and standing (range,
0.9 to 4.0 mm Hg) diastolic BP values. Mean
supine and standing pulse rates showed minimal
changes on day 7 of period 1 relative to baseline values.
In period 2, after treatment with HCTZ alone (on day
28), mean supine and standing systolic and diastolic BP
values were minimally changed relative to baseline
values. Mean supine pulse rates also showed minimal706changes on day 28 of period 2 compared with baseline,
but mean standing pulse rates were slightly increased
(range, 1.0 to 9.1 bpm). After further treatment with
canagliﬂozin þ HCTZ for 7 days in period 2 (on day
35), mean supine and standing systolic BP values were
slightly decreased relative to baseline values (ranges,
0.4 to 3.4 mm Hg and 0.7 to 8.2 mm Hg,
respectively). Mean supine diastolic BP showed no
notable changes, whereas mean standing diastolic BP
was slightly decreased (range, 0.3 to 3.4 mm Hg).
Mean supine pulse rates did not notably change, but
mean standing pulse rates were increased relative to
baseline values (range, 6.5 to 16.1 bpm).
A single event of orthostatic hypotension, as de-
ﬁned by measurement of vital signs (see Methods),
occurred during canagliﬂozin treatment alone in pe-
riod 1; 5 events of orthostatic hypotension were
reported in 4 participants during treatment with
HCTZ alone in period 2; and 7 events of orthostatic
hypotension were reported in 5 participants during
coadministration of canagliﬂozin þ HCTZ.Volume 36 Number 5
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Hypertension affects 70% of patients with diabe-
tes,26 so it is likely that some individuals will receive
concurrent therapy with canagliﬂozin and an
antihypertensive medication such as HCTZ. A
pharmacodynamic interaction between canagliﬂozin
and HCTZ could occur because both target the
kidney and have a diuretic effect.4–6,17,18 In the
present study, potential pharmacodynamic interac-
tions as well as the tolerability of canagliﬂozin
coadministered with HCTZ were assessed in healthy
adults; pharmacokinetic properties with canagliﬂozin þ
HCTZ coadministration were also evaluated.
The 300-mg canagliﬂozin dose was chosen because
this is the maximal dose evaluated in the Phase III
program and the maximal dose approved in the United
States.11 HCTZ is effective over the range of 12.5 to
50 mg once daily; therefore, a dose of 25 mg was
chosen for this study. Plasma concentrations of
canagliﬂozin were assessed 7 days after initiation of
dosing (on day 7 of period 1 and day 35 of period 2)
because plasma canagliﬂozin concentrations have been
shown to achieve steady state within 6 days with the
300-mg dose.27 HCTZ treatment has been associated
with a decrease in extracellular ﬂuid volume and thus
takes several weeks to achieve steady-state levels.20
HCTZ was administered alone for 28 days so that
acute extracellular volume changes were attenuated.
Although a ﬁxed-sequence study design has limitations
(ie, potential period and crossover effects), it was used
in the current study due to the required 28-day
administration of HCTZ in period 2 and to allow
for the evaluation of each study drug alone and in
combination within the same participant group. The
14-day washout between periods was sufﬁcient be-
cause the half-life of canagliﬂozin is 12 hours,11 and
in previous studies pharmacodynamic activity of
canagliﬂozin returned to baseline within 5 days after
the last dose was administered (unpublished observa-
tions, Janssen, 2012).
Coadministration of canagliﬂozin þ HCTZ re-
sulted in 12% and 15% increases in mean canagli-
ﬂozin AUCτ,ss and Cmax,ss, respectively, relative to
canagliﬂozin alone. Plasma canagliﬂozin concentra-
tions achieved with 300 mg/d were sufﬁcient to
provide near-maximal lowering of RTG throughout
the full 24-hour period in patients with T2DM.28
Furthermore, in other studies, twice-daily doses of
canagliﬂozin 300 mg achieved mean plasma AUCτ,ssMay 2014that was 68% higher than that with the canagli-
ﬂozin 300-mg once-daily dose þ HCTZ in this study
(unpublished data, Janssen, 2012), but glycemic efﬁ-
cacy was comparable between canagliﬂozin 300 mg
once- and twice-daily doses in a previous study.3
Based on the efﬁcacy and tolerability results
observed in prior Phase I and II studies3,25,27,28 and
the pharmacodynamic ﬁndings presented here, the
small increases in canagliﬂozin AUCτ,ss and Cmax,ss
when canagliﬂozin is coadministered with HCTZ are
unlikely to be clinically important. Repeated doses of
canagliﬂozin 300 mg/d had minimal effects on the
steady-state pharmacokinetic properties of HCTZ.
Values of RTG are reported to be 10 to 11 mmol/L
(180–200 mg/dL) in healthy participants without any
pharmacologic intervention29–31; as anticipated based
on results from other clinical canagliﬂozin trials,12,25,28
mean RTG was lowered to 3.3 mmol/L (60 mg/dL)
with canagliﬂozin treatment in the present study.
Although plasma canagliﬂozin levels increased during
coadministration with HCTZ, only a slight change in
the direct pharmacodynamic effect of canagliﬂozin (ie,
further RTG lowering) was observed. The difference in
RTG lowering by canagliﬂozin with and without coad-
ministration with HCTZ was 0.3 mmol/L (5 mg/dL),
and this difference is unlikely to have an impact on the
efﬁcacy of canagliﬂozin. Consistent with this, UGE0–24 h
and 24-hour MPG were generally similar between
canagliﬂozin þ HCTZ coadministration and canagli-
ﬂozin alone in this study.
No unanticipated tolerability concerns were identi-
ﬁed during coadministration of canagliﬂozin þ
HCTZ. Three cases of fungal infection were reported
during treatment with canagliﬂozin alone, were con-
sidered mild, and were resolved by the end-of-study
visit. Five cases of rash were reported during treat-
ment with canagliﬂozin alone, all of which were mild;
rash and urticaria were observed with a low preva-
lence across Phase III studies of canagliﬂozin.32 TEAEs
related to the diuretic effects of each drug
(eg, orthostatic hypotension) were of particular
interest, but were not greatly increased in prevalence
or severity during combined treatment compared with
either drug alone. However, 2 participants
experienced syncope during coadministration of
canagliﬂozin þ HCTZ; both episodes were mild and
reﬂected volume depletion during combined therapy.
The reductions observed in mean systolic and dia-
stolic BP values (supine and standing) following707
Clinical Therapeuticscanagliﬂozin treatment for 7 days were generally com-
parable to placebo-subtracted BP reductions reported in
other canagliﬂozin studies4,5,7,9,10; however, these
changes may not be entirely attributable to canagliﬂozin
because the present study did not include a placebo
control group. HCTZ treatment alone for 1 month led
to minimal changes in mean systolic and diastolic BP
values (supine and standing), consistent with the effects
of HCTZ in normotensive individuals.33,34 After coad-
ministration of canagliﬂozin þ HCTZ for 7 days, mean
standing and supine systolic BP values were slightly
lower than baseline values. Of note, the conditions of
this study were designed to amplify any potential
interactions between canagliﬂozin and HCTZ related
to BP effects. Taken together, ﬁndings related to BP and
pulse rate during canagliﬂozin and HCTZ monotherapy
periods, and during the combined canagliﬂozin þ
HCTZ treatment period, do not suggest any major
hemodynamic interactions.
As anticipated, HCTZ treatment alone increased
potassium excretion without signiﬁcant changes in
serum potassium levels. Coadministration of canagli-
ﬂozin þ HCTZ led to a slight increase in potassium
excretion and had little effect on serum potassium
compared with HCTZ treatment alone. Unexpectedly,
sodium excretion was relatively unchanged with either
canagliﬂozin or HCTZ administered alone, which may
be related to low sodium content in the diet or to an
underlying low baseline sodium excretion. Coadminis-
tration of canagliﬂozin þ HCTZ resulted in a greater
increase in sodium excretion. Serum sodium and
potassium levels were unchanged with canagliﬂozin
treatment alone, and both were slightly decreased after
treatment with HCTZ alone, as expected based on the
known effects of HCTZ.35 Even though FEsodium
increased with the coadministration of canagliﬂozin þ
HCTZ, the combined treatment did not appear to
inﬂuence serum sodium and potassium levels beyond
those observed with HCTZ alone. Serum urate was
markedly decreased with canagliﬂozin alone and
increased with HCTZ alone, consistent with the
known effect of HCTZ to inhibit uric acid excretion.
The observed changes from baseline in 24-hour crea-
tinine clearance or serum creatinine were minimal after
any treatment and are not expected to have a clinical
impact. Increases in BUN seen in each period were
reﬂective of the independent effects of each drug. Mean
daily urine volumes, mean urinary sodium excretion,
and FEsodium were only slightly affected by treatment708with canagliﬂozin, HCTZ, or the combination. HCTZ
alone increased FEpotassium and FEmagnesium and de-
creased FEcalcium, consistent with the known effects of
thiazides on these electrolytes36,37; however, the total
and fractional excretion of these electrolytes were largely
unaffected by the addition of canagliﬂozin to HCTZ.
A limitation of this study was that it was conducted
in healthy participants and not in patients with
T2DM, the intended treatment population. Although
data describing the combined effects of canagliﬂozin
and diuretics in patients with T2DM have not been
published, unpublished data from Phase III studies of
canagliﬂozin describing ﬁndings in patients with
T2DM who were taking both canagliﬂozin and
diuretics are described to provide context. Changes
from baseline in systolic BP and the prevalence of AEs
related to volume depletion have been evaluated in
patients with T2DM using pooled data from patients
enrolled in Phase III studies of canagliﬂozin who were
on background therapy with a diuretic (eg, thiazides,
furosemide). In a pooled, placebo-controlled popula-
tion (N = 4158), reductions in systolic BP observed
with canagliﬂozin relative to placebo were not notably
different between subgroups of patients who were on
(35.9%) or not on (64.1%) diuretics at baseline
(unpublished data, Janssen, 2012). Among patients
on diuretics (35.2%) in a larger pooled population
(N = 9439), which included more patients with
comorbidities such as cardiovascular and renal disease
compared with the placebo-controlled population,
those who received canagliﬂozin had a higher inci-
dence of volume-depletion AEs (eg, orthostatic hypo-
tension, postural dizziness) compared with those who
received control (2.7%, 5.4%, and 2.1% with cana-
gliﬂozin 100 and 300 mg and controls, respectively)
(unpublished data, Janssen, 2012). The increased
risk for volume-depletion AEs was primarily noted
with canagliﬂozin 300 mg relative to canagliﬂozin
100 mg and controls in patients on loop diuretics
(eg, furosemide; 8.8%, 3.2%, and 4.7%, respec-
tively)32; a smaller increase in the incidence of
volume-depletion AEs was observed with canagliﬂozin
versus controls in patients on nonloop diuretics, such
as thiazide diuretics (2.6%, 4.4%, and 1.4% for
canagliﬂozin 100 and 300 mg and controls, respec-
tively) (unpublished data, Janssen, 2012). These re-
sults from Phase III studies are generally consistent
with ﬁndings from the present study demonstrating no
notable interactions between canagliﬂozin and HCTZ.Volume 36 Number 5
D. Devineni et al.CONCLUSION
This study in healthy participants showed that coad-
ministration of canagliﬂozin þ HCTZ had no notable
pharmacokinetic or pharmacodynamic interactions,
and there was no evidence of any unexpected drug–
drug interactions based on clinical laboratory or other
tolerability end points.ACKNOWLEDGMENTS
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